MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
12/11/2008 at 07:30 AM
First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that its licensing partner, Centocor R&D Inc., has enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody. A Phase 1 clinical trial using the same antibody in oncology patients was initiated in 2007 and is ongoing. The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys's core technology, to enter human clinical trials in a second indication with partners. The initiation of the Phase 2 trial and the IND in a new indication trigger clinical milestone payments to MorphoSys.
"Today's news marks further significant progress within our partnered therapeutic antibody business and underpins the variety of commercial opportunities inherent in our pipeline," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Indication broadening is at the heart of the commercial success of several antibody therapies currently on the market. For MorphoSys, additional indications represent further value for our partnered drug pipeline as it leads to higher clinical milestones and royalty-based income."
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com
xxxxxxxxxxxxxxxxxx
I'm sure this is the subject:
clinicaltrials.gov
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) |
